Presentació dels Hospitals
Col·labora Bipodex Col·labora

Grup d’Estudi en Malalties Metabòliques Associades a la Insulin-Resistència (GEMMAIR)

MALALTIES METABÒLIQUES I NUTRICIÓ
OBESITAT PATOGÈNIA BIOMARCADORS DIANES TERAPÈUTIQUES MALALTIA DEL FETGE GRAS NO ALCOHÒLIC
OBJECTIUS

GEMMAIR té una llarga trajectòria en l’estudi de la fisiopatologia de l’obesitat i les malalties associades. Actualment, el grup centra principalment la seva recerca en l’estudi de l’hepatopatia grassa no alcohòlica i les seves comorbiditats, com són l’obesitat, la diabetis mellitus de tipus 2 i la síndrome metabòlica, amb la finalitat de definir nous mecanismes moleculars implicats en la malaltia, i trobar possibles biomarcadors i potencials dianes terapèutiques.

RESPONSABLES

  • Dra. Teresa Auguet Quintillà

  • PRESENTACIÓ
  • Línies de recerca
  • MEMBRES DEL GRUP
  • PROJECTES
  • TRANSFERÈNCIA
  • Publicacions
  • CONTACTE

El Grup d’Estudi en Malalties Metabòliques Associades a la Insulin-Resistència (GEMMAIR) és un grup de recerca clínica i bàsica format per un equip multidisciplinari. Aquest es compon de personal investigador mèdic i experimental que pertany a l’Hospital Universitari de Tarragona Joan XXIII i a l’Hospital Universitari Sant Joan de Reus: metges internistes, cirurgians, patòlegs, biòlegs moleculars i tècnics de laboratori.

GEMMAIR té una trajectòria de més de 25 anys d’experiència en l’estudi de malalties hepàtiques cròniques i de més de 15 anys en l’estudi de l’obesitat i les malalties associades. Tanmateix, GEMMAIR està acreditat com a grup consolidat per l’Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) des de l’any 2009 i és un grup de recerca reconegut per la Universitat Rovira i Virgili (URV).

GEMMAIR ha realitzar diverses col·laboracions en l’àmbit nacional i internacional; a més el grup té una gran vinculació amb l’àmbit acadèmic, donat que la major part dels membres del grup son professors de la URV. També s’hi han dut a terme un gran nombre de tesis doctorals i treballs de final de grau i de màster, pel que GEMMAIR, té experiència en la formació del personal investigador novell.

  • Estudi de citoquines i adipocitoquines en la fisiopatologia de l’obesitat, la síndrome metabòlica i la malaltia de fetge gras no alcohòlic (MFGNA).
  • Expressió gènica, factors transcripcionals i epigenètica en la MFGNA.
  • Estudi dels metabòlits derivats de la microbiota en la MFGNA.
  • Ciències òmiques (metabolòmica, miRNòmica i proteòmica) en el diagnòstic no invasiu de l’esteatohepatitis no alcohòlica.
  • Ciències òmiques (metabolòmica i proteòmica) en l’estudi de la placa arterial arterioscleròtica.
  • Biomarcadors pronòstics de la COVID-19 en pacients amb obesitat i/o síndrome metabòlica.
  • Malaltia tromboembòlica venosa.

  • Microplastics: Dietary intake, impact on gut and promotion on liver damage (MP-DiGuLi). PROYECTOS DE GENERACIÓN DE CONOCIMIENTO 2022 PLAN ESTATAL. IP: Martí Nadal i Joaquim Rovira. IISPV. 2024-2027. 252.250,00€

  • WASTEwater as a source of knowledge on SARS-CoV-2 and other potentially pandemic VIRuses: a One Health approach (VIRWASTE). AGAUR. 01/05/2021-31/12/2023. 316.000€.

  • Biomarcadores de pronóstico circulantes y celulares para la progresión de COVID19 enpacientes con infección por SARS-CoV-2 utilizando ciencia multiómica. AGAUR. FRANCISCO VIDAL MARSAL. (FUNDACIÓ PRIVADA IISPV). 30/03/2020-31/12/2020.
    201.070,79 €.

  • PI16/00498, Papel de la disbiosis intestinal en la patogenia de la enfermedad del hígado graso no alcohólico a través de la regulación de la homeostasis lipídica hepática. Instituto de Salud Carlos III. Maria Teresa Auguet Quintillà. URV. 01/01/2017-31/12/2019. 71.500€.

  • 2016PFR-URV-B2-72, Grup d’Estudi de Malalties Metabòliques associades a Insulin
    Resistència (GEMMAIR) Universitat Rovira i Virgili. Cristobal Manuel Richart Jurado.
    URV. 01/01/2017-30/06/2018. 6.572,17 €.

  • 2016PFR-URV-B2-72, Programa de suport als grups de recerca reconeguts. Grup d’Estudi
    de Malalties Metabòliques associades a Insulin Resistència (GEMMAIR) Universitat
    Rovira i Virgili. Cristobal Manuel Richart Jurado. URV. 01/01/2017- 31/12/2017.
    6.572,17 €.

  • 2015PFR-URV-B2-72, Grup d’Estudi de Malalties Metabòliques associades a Insulin
    Resistència (GEMMAIR) Universitat Rovira i Virgili. Cristobal Manuel Richart Jurado.URV.
    01/01/2015-31/12/2017. 6.839 €.

  • 2015PFR-URV-B2-72, Programa de suport als grups de recerca reconeguts. Grup d’Estudi
    de Malalties Metabòliques associades a Insulin Resistència (GEMMAIR) Universitat
    Rovira i Virgili. Cristobal Manuel Richart Jurado.URV. 01/01/2015- 31/12/2017. 6.839 €.

    Assajos clínics:

  • A Phase IIb/III Randomized, Double-blind,Placebo-controlled Study to Evaluate the Safety and Efficacy of Cotadutide in Participants with Non-cirrhotic Non-Alcoholic
    Steatohepatitis with Fibrosis (D5671C00006). AstraZenecaAB. Desde 2022. IP: Dr. David Riesco

  • Phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study to evaluate the efficacy and safety of recombinant human plasma gelsolin (RHUPGSN) added to standard of care for treatment of subjects with severe covid-19 pneumonia.
    Desde 2020. IP: Dra. T. Auguet

  • Safety and efficacy of favipipravir in COVID-19 patients with pneumonia. A randomized, double blind, placebo controlled study (FAVID01-20-SP). Ferrer Internacional, S.A. Desde 2020. IP: Dra. T. Auguet

    Año

    LC/MS-Based Untargeted Metabolomics Study in Women with Nonalcoholic Steatohepatitis Associated with Morbid Obesity

    Bertran, L.; Capellades, J.; Abelló, S.; Durán-Bertran, J.; Aguilar, C.; Martinez, S.; Sabench, F.; Correig, X.; Yanes, O.; Auguet, T.; Richart, C. LC/MS-Based Untargeted Metabolomics Study in Women with Nonalcoholic Steatohepatitis Associated with Morbid Obesity. Int. J. Mol. Sci. 2023, 24, 9789.

    https://doi.org/10.3390/ijms24129789

    LC/MS-Based Untargeted Metabolomics Analysis in Women with Morbid Obesity and Associated Type 2 Diabetes Mellitus

    Auguet, T.; Bertran, L.; Capellades, J.; Abelló, S.; Aguilar, C.; Sabench, F.; del Castillo, D.; Correig, X.; Yanes, O.; Richart, C. LC/MS-Based Untargeted Metabolomics Analysis in Women with Morbid Obesity and Associated Type 2 Diabetes Mellitus. Int. J. Mol. Sci. 2023, 24, 7761.

    https://doi.org/10.3390/ijms24097761

    Increased Hepatic ATG7 mRNA and ATG7 Protein Expression in Nonalcoholic Steatohepatitis Associated with Obesity

    Barrientos-Riosalido, A.; Real, M.; Bertran, L.; Aguilar, C.; Martínez, S.; Parada, D.; Vives, M.; Sabench, F.; Riesco, D.; Castillo, D.D.; Richart, C.; Auguet, T. Increased Hepatic ATG7 mRNA and ATG7 Protein Expression in Nonalcoholic Steatohepatitis Associated with Obesity. Int. J. Mol. Sci. 2023, 24, 1324.

    https://doi.org/10.3390/ijms24021324

    The Role of Olfactomedin 2 in the Adipose Tissue–Liver Axis and Its Implication in Obesity-Associated Nonalcoholic Fatty Liver Disease

    Barrientos-Riosalido, A.; Bertran, L.; Vilaró-Blay, M.; Aguilar, C.; Martínez, S.; Paris, M.; Sabench, F.; Riesco, D.; Binetti, J.; Castillo, D.D.; Richart, C.; Auguet, T. The Role of Olfactomedin 2 in the Adipose Tissue–Liver Axis and Its Implication in Obesity-Associated Nonalcoholic Fatty Liver Disease. Int. J. Mol. Sci. 2023, 24, 5221.

    https://doi.org/10.3390/ijms24065221

    Expression of STING in Women with Morbid Obesity and Nonalcoholic Fatty Liver Disease

    Bertran, L.; Adalid, L.; Vilaró-Blay, M.; Barrientos-Riosalido, A.; Aguilar, C.; Martínez, S.; Sabench, F.; del Castillo, D.; Porras, J.A.; Alibalic, A.; Richart, C.; Auguet, T. Expression of STING in Women with Morbid Obesity and Nonalcoholic Fatty Liver Disease. Metabolites 2023, 13, 496.

    https://doi.org/10.3390/metabo13040496

    Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19

    Matuozzo, D., Talouarn, E., Marchal, A., […] Auguet, T., et al. Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19. Genome Med 15, 22 (2023).

    https://doi.org/10.1186/s13073-023-01173-8

    Evolving mortality and clinical outcomes of hospitalized subjects during successive COVID-19 waves in Catalonia, Spain. Global epidemiology. 4.

    Roso-Llorach, Albert; Serra-Picamal, Xavier; Cos, Francesc X; et al; Paredes, Roger.

    https://doi.org/10.1016/j.gloepi.2022.100071

    Lipocalin, Resistin and Gut Microbiota-Derived Propionate Could Be Used to Predict Metabolic Bariatric Surgery Selected Outcomes. Processes. 10.

    Auguet, Teresa (AC); López-Dupla, Miguel; Ramos, Jessica; et al; Richart, Cristóbal.

    https://doi.org/10.3390/pr10010143

    Fetuin-A, inter-α-trypsin inhibitor, glutamic acid and ChoE (18:0) are key biomarkers in a panel distinguishing mild from critical coronavirus disease 2019 outcomes. Clinical and Translational Medicine. 12-1, pp.e704-e704.

    Reverté, Laia; Yeregui, Elena; Olona, Montserrat; et al; Auguet, Teresa; Study Group, COVIDOMICS.

    https://doi.org/10.1002/ctm2.704

    Resistin and IL-15 as Predictors of Invasive Mechanical Ventilation in COVID-19 Pneumonia Irrespective of the Presence of Obesity and Metabolic Syndrome. Journal of Personalized Medicine. 12-3.

    Perpiñan, Carles; Bertran, Laia; Terra, Ximena; et al; Auguet, Teresa; behalf of COVID-19 Study Group.

    https://doi.org/10.3390/jpm12030391

    Venous Thrombosis within 30 Days after Vaccination against SARS-CoV-2 in a Multinational Venous Thromboembolism Registry Viruses. 14-2.

    Bikdeli, Behnood; Jiménez, David; Demelo-Rodriguez, Pablo; et al; the RIETE Investigators, for.

    https://doi.org/10.3390/v14020178

    Identification of the Potential Molecular Mechanisms Linking RUNX1 Activity with Nonalcoholic Fatty Liver Disease, by Means of Systems Biology

    Bertran, L.; Eigbefoh-Addeh, A.; Portillo-Carrasquer, M.; Barrientos-Riosalido, A.; Binetti, J.; Aguilar, C.; Ugarte Chicote, J.; Bartra, H.; Artigas, L.; Coma, M.; Richart, C.; Auguet, T. Identification of the Potential Molecular Mechanisms Linking RUNX1 Activity with Nonalcoholic Fatty Liver Disease, by Means of Systems Biology. Biomedicines 2022, 10, 1315.

    https://doi.org/10.3390/biomedicines10061315

    NASH Presence is Associated with a Lower Weight Loss One and 2 Years After Bariatric Surgery in Women with Severe Obesity

    Sabench, F., Bertran, L., Vives, M. et al. NASH Presence is Associated with a Lower Weight Loss One and 2 Years After Bariatric Surgery in Women with Severe Obesity. OBES SURG 32, 3313–3323 (2022).

    https://doi-org.sabidi.urv.cat/10.1007/s11695-022-06175-w

    New Insights of OLFM2 and OLFM4 in Gut-Liver Axis and Their Potential Involvement in Nonalcoholic Fatty Liver Disease

    Bertran, L.; Jorba-Martin, R.; Barrientos-Riosalido, A.; Portillo-Carrasquer, M.; Aguilar, C.; Riesco, D.; Martínez, S.; Vives, M.; Sabench, F.; Castillo, D.D.; Richart, C.; Auguet, T. New Insights of OLFM2 and OLFM4 in Gut-Liver Axis and Their Potential Involvement in Nonalcoholic Fatty Liver Disease. Int. J. Mol. Sci. 2022, 23, 7442.

    https://doi.org/10.3390/ijms23137442

    The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies

    Jérémy Manry,  Paul Bastard, Adrian Gervais, […] Teresa Auguet, et al. The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies 2022; 119 (21) e2200413119

    https://doi.org/10.1073/pnas.2200413119

    Are Ingested or Inhaled Microplastics Involved in Nonalcoholic Fatty Liver Disease?

    Auguet, T.; Bertran, L.; Barrientos-Riosalido, A.; Fabregat, B.; Villar, B.; Aguilar, C.; Sabench, F. Are Ingested or Inhaled Microplastics Involved in Nonalcoholic Fatty Liver Disease? Int. J. Environ. Res. Public Health 2022, 19, 13495.

    https://doi.org/10.3390/ijerph192013495

    Increased Secreted Frizzled-Related Protein 5 mRNA Expression in the Adipose Tissue of Women with Nonalcoholic Fatty Liver Disease Associated with Obesity

    Bertran, L.; Portillo-Carrasquer, M.; Barrientos-Riosalido, A.; Aguilar, C.; Riesco, D.; Martínez, S.; Culebradas, A.; Vives, M.; Sabench, F.; Castillo, D.D.; Richart, C.; Auguet, T. Increased Secreted Frizzled-Related Protein 5 mRNA Expression in the Adipose Tissue of Women with Nonalcoholic Fatty Liver Disease Associated with Obesity. Int. J. Mol. Sci. 2022, 23, 9871.

    https://doi.org/10.3390/ijms23179871

    Demographic, clinical, and functional determinants of antithrombotic treatment in patients with nonvalvular atrial fibrillation. BMC Cardiovascular Disorders.

    Mostaza, Jose Maria; Suarez Carmen; et al; on behalf of the PERFILAR study investigators.

    https://doi.org/10.1186/s12872-021-02019-0

    X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19. SCIENCE IMMUNOLOGY. 2021. 6-62.

    Asano, Takaki; Boisson, Bertrand; et al; Casanova Jean-Laurent.

    https://doi.org/10.1126/sciimmunol.abl4348

    Expression of Jejunal Taste Receptors in Women with Morbid Obesity. NUTRIENTS.

    Bertran L; Portillo-Carrasque M; Martinez S; et al; Auguet T.

    https://doi.org/10.3390/nu13072437

    Deregulation of Secreted Frizzled-Related Protein 5 in Nonalcoholic Fatty Liver Disease Associated with Obesity. International Journal of Molecular Sciences.

    Villar, B; Bertran L; Aguilar C; et al; Auguet T.

    https://doi.org/10.3390/ijms22136895

    The Potential Protective Role of RUNX1 in Nonalcoholic Fatty Liver Disease. International Journal of Molecular Sciences.

    Bertran L; Pastor A; Portillo-Carrasquer M; et al; Auguet T.

    https://doi.org/10.3390/ijms22105239

    Predictive Biomarkers of COVID-19 Severity in SARS-CoV-2 Infected Patients with Obesity and Metabolic Syndrome. Journal of Personalized Medicine.

    Perpiñan C; Bertran L; Terra X; et al; Auguet T.

    https://doi.org/10.3390/jpm11030227

    Rivaroxaban or apixaban in fragile patients with acute venous thromboembolism Thrombosis Research. 193, pp.160-165.

    Trujillo-Santos J, Beroiz P, Moustafa F, Alonso A, Morejon E, López-Reyes R, Casado I, Porras JA, Flores K, López-Núñez JJ, Monreal M; RIETE Investigators. Rivaroxaban or apixaban in fragile patients with acute venous thromboembolism. Thromb Res. 2020 Sep;193:160-165.

    doi: 10.1016/j.thromres.2020.06.035

    Venous Thromboembolism in Patients with Autoimmune Disorders: Findings from the RIETE Registry Angiology. 71-2, pp.131- 138.

    PR Sada; JJ López-Nuñez; A Samperiz; et al.

    https://doi.org/10.1177/0003319719875895

    Deregulated Serotonin Pathway in Women with Morbid Obesity and NAFLD. LIFE.

    Binetti J; Bertran L; Riesco D; et al; Auguet T.

    https://doi.org/10.3390/life10100245

    Auto-antibodies against type I IFNs in patients with life-threatening COVID-19. SCIENCE. 2020. pp.423.

    Bastard, Paul; Rosen, Lyndsay B; et al; Casanova Jean-Laurent.

    https://doi.org/10.1126/science.abd4585

    Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. SCIENCE. 2020. pp.422.

    Zhang, Qian; Bastard, Paul; et al; Casanova Jean-Laurent.

    https://doi.org/10.1126/ science.abd4570

    Hepatocyte Notch Signaling Deregulation Related to Lipid Metabolism in Women with Obesity and Nonalcoholic Fatty Liver. Obesity. 28-8, pp.1487-1493.

    Auguet, Teresa; Bertran, Laia; Binetti, Jessica; et al; Richart, Cristóbal.

    https://doi.org/10.1002/oby.22873

    Implicaciones pronósticas del daño miocárdico en pacientes con y sin diagnóstico confirmado de COVID-19 atendidos en un hospital universitario. Rev Esp Cardiol.

    Alfredo Bardaji; Anna Carrasquer; Raul Sánchez-Giménez; et al; 2020.

    https://doi.org/10.1016/j.recesp.2020.08.009

    Relationship between IL-8 Circulating Levels and TLR2 Hepatic Expression in Women with Morbid Obesity and Nonalcoholic Steatohepatitis. International Journal of Molecular Sciences. 21-11.

    Auguet, Teresa; Bertran, Laia; Binetti, Jessica; et al; Richart, Cristóbal. 2020.

    https://doi.org/10.3390/ijms21114189

    Relationship between IL-8 Circulating Levels and TLR2 Hepatic Expression in Women with Morbid Obesity and Nonalcoholic Steatohepatitis. International Journal of Molecular Sciences. 21-11.

    Aragonès, G.; Colom Pellicer, M.; Aguilar, C.; et al; Auguet, T.

    https://doi.org/10.1038/s41366-019-0430-0

    Deregulated Serotonin Pathway in Women with Morbid Obesity and NAFLD. LIFE.

    Binetti J, Bertran L, Riesco D, Aguilar C, Martínez S, Sabench F, Porras JA, Camaron J, Castillo DD, Richart C, Auguet T. Deregulated Serotonin Pathway in Women with Morbid Obesity and NAFLD. Life (Basel). 2020 Oct 16;10(10):245.

    doi: 10.3390/life10100245

    Auto-antibodies against type I IFNs in patients with life-threatening COVID-19. SCIENCE. 2020. pp.423.

    Bastard, Paul; Rosen, Lyndsay B; et al; Casanova Jean-Laurent.

    https://doi.org/10.1126/science.abd4585

    Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. SCIENCE. 2020. pp.422.

    Zhang, Qian; Bastard, Paul; et al; Casanova Jean-Laurent.

    https://doi.org/10.1126/ science.abd4570

    Hepatocyte Notch Signaling Deregulation Related to Lipid Metabolism in Women with Obesity and Nonalcoholic Fatty Liver. Obesity. 28-8, pp.1487-1493.

    Auguet, Teresa; Bertran, Laia; Binetti, Jessica; et al; Richart, Cristóbal.

    https://doi.org/10.1002/oby.22873

    Circulating microbiota-derived metabolites: a “liquid biopsy?. International journal of obesity.

    O Avnery; M Martin; A Bura-Riviere; et al. 2019.

    https://doi.org/10.1111/joim.12969

    Circulating microbiota-derived metabolites: a “liquid biopsy?. International journal of obesity.

    Mastroiacovo D; Dentali F; di Micco P; et al. RIETE Investigators.

    https://doi.org/10.1183/13993003.01677-2018

    D-dimer levels and risk of recurrence following provoked venous thromboembolism: findings from the RIETE registry. J Intern Med.

    O Avnery; M Martin; A Bura-Riviere; et al.

    https://doi.org/10.1111/joim.12969

    Venous Thromboembolism in Patients with Autoimmune Disorders: Findings from the RIETE Registry. Angyology. SAGE. pp.1- 8.

    Binetti J; Bertran L; Riesco D; et al; Auguet T.

    https://doi.org/10.3390/life10100245

    Rate and duration of hospitalisation for acute pulmonary embolism in the real-world clinical practice of different countries: analysis from the RIETE registry. 903624 – European Respiratory Journal. 53-2.

    Alfredo Bardaji; Anna Carrasquer; Raul Sánchez-Giménez; et al; 2020.

    https://doi.org/10.1016/j.recesp.2020.08.009

    Rate and duration of hospitalisation for acute pulmonary embolism in the real-world clinical practice of different countries: analysis from the RIETE registry. 903624 – European Respiratory Journal. 53-2.

    Aragonès, G.; Colom Pellicer, M.; Aguilar, C.; et al; Auguet, T.

    https://doi.org/10.1038/s41366-019-0430-0

    Gut Microbiota-Derived Mediators as Potential Markers in Nonalcoholic Fatty Liver Disease. Biomed Research International.

    Mastroiacovo D; Dentali F; di Micco P; et al. RIETE Investigators.

    https://doi.org/10.1183/13993003.01677-2018

    Low circulating levels of neurotensin in women with non-alcoholic fatty liver disease associated to severe obesity. Obesity. 26-2, pp.274-278.

    Auguet T; Aragonès G; Berlanga A; et al; Richart C.

    https://doi.org/10.1002/oby.22058

    Real-life Use of Anticoagulants in Venous Thromboembolism with a Focus on Patients with Exclusion Criteria for Direct Oral Anticoagulants Clinical Pharmacology & Therapeutics. 103-4, pp.684-691.

    Moustafa, Farès; Pesavento, Raffaele; di Micco, Pierpaolo; et al; RIETE Investigators, the.

    https://doi.org/10.1002/cpt.781

    Anemia and bleeding in patients receiving anticoagulant therapy for venous thromboembolism.910696 – Journal of Thrombosis and Thrombolysis. 45-3, pp.360-368.

    Kuperman A; López-Reyes R; Bosco LJ; et al; RIETE Investigators.

    https://doi.org/10.1007/s11239-018-1610-9

    Characteristics, treatment patterns and outcomes of patients presenting with venous thromboembolic events after knee arthroscopy in the RIETE Registry

    Weinberg I; Giri J; Kolluri R; et al; RIETE Investigators.

    https://doi.org/10.1007/s11239-018-1736-9

    Thirty-day outcomes in patients with acute pulmonary embolism who discontinued anticoagulant therapy before 90 days 900566 – American Heart Journal. 206, pp.1-10.

    Nieto JA; Vicente JA; Prieto LM; et al; RIETE Investigators.

    https://doi.org/10.1016/j.ahj.2018.08.014

    Targeted metabolomic approach in men with carotid plaque. Plos One. 13.

    Auguet T; Aragonès G; Colom M; Aguilar C; Martín-Paredero V; Canela N; Ruyra X; Richart C.

    https://doi.org/10.1371/journal.pone.0200547

    Development of a Risk Prediction Score for Occult Cancer in Patients With VTE. CHEST. 151-3, pp.564.

    ara-Palomares, L.; Otero, R.; Jimenez, D.; et al; Mazzolai,L.

    https://doi.org/10.1016/j.chest.2016.10.025

    Hepcidin in morbidly obese women with non-alcoholic fatty liver disease. PlosOne.

    Auguet T; Aragonès G; Berlanga A; et al; Richart C.

    https://doi.org/10.1371/journal.pone.0187065

Membres De L’equip

  • Responsable de grup

    • Dra. Teresa Auguet Quintillà

  • Investigadors clínics

    • José Antonio Porras Ledante
    • David Riesco Acevedo
    • Salomé Martínez González
    • Jessica Binetti
    • Ajla Alibalic
    • Marta París Sans
    • Margarida Vives Espelta
    • Fàtima Sabench Pereferrer
    • Dr. Daniel del Castillo Déjardin

  • Investigador emèrit

    • Cristóbal Manuel Richart Jurado

  • Investigadors post-doctorals

    • Laia Bertran Ramos
    • Javier Ugarte Chicote
    • Joanna Jurek

  • Investigadors pre-doctorals

    • Laia Adalid
    • Joan Durán-Bertran
    • Carmen Arto
    • Razie Mahmoodian
    • Helena Clavero

  • Bioinformàtica

    • Elena Cristina Rusu Hutu

  • Personal tècnic de laboratori

    • Carmen Aguilar Crespillo
    • Andrea Barrientos Riosalido

Altres grups de Malalties Metabòliques i Nutrició

Veure tots